Celltrion’s Remsima Wins No. 1 Prescription Spot in Japan; Share Tops 90% in Asia, Latin America — BigGo Finance
South Korea’s Celltrion (068270) has beaten original drugs to take the lead in Japan’s autoimmune disease treatment market.…
#Conflict #Conflicts #War #Brazil #Celltrion #CostaRica #Herzuma #Infliximab #japan #Latinamerica #Omlyclo #Remsima #RemsimaSC #Singapore #Steqeyma #Stoboclo-Osenvelt #Truxima #Vegzelma
https://www.europesays.com/3320910/
